Clinical Trials Logo

Clinical Trial Summary

To evaluate the contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen and to evaluate the safety compared to LNG 100 mg/EE 20 mg for 21 days followed by a 7-day hormone-free interval in a cyclic regimen.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training


Related Conditions & MeSH terms


NCT number NCT00248963
Study type Interventional
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status Completed
Phase Phase 3
Completion date October 2004

See also
  Status Clinical Trial Phase
Completed NCT01388491 - A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women Phase 2
Completed NCT01252186 - A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women Phase 2
Not yet recruiting NCT06426459 - Social Media Usage in Adolescent Girls
Recruiting NCT02398903 - Evaluation of Hormonal Contraceptive Treatments in Obese Women
Completed NCT00302666 - Bleeding Pattern Study Phase 3
Completed NCT00739622 - TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women. Phase 1
Completed NCT01291004 - A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives Phase 1
Recruiting NCT01318005 - Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation N/A
Recruiting NCT02021097 - Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception Phase 3
Completed NCT00778609 - Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache Phase 3
Completed NCT00972439 - Oral Contraceptive (OC) Progestin Dose and Breast Proliferation N/A
Completed NCT01076582 - Comparative Trial in Hormone Withdrawal Associated Symptoms Phase 3
Completed NCT00471991 - Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition Phase 2